Unity Biotechnology (UBX)

• Market cap: $16.9M
• 1 day: 4.19%
• 5 days: -4.76%
• 1 month: -15.97%
• 3 months: -30.56%
• 6 months: -29.08%
• Year to date: -47.92%
• 1 year: -41.52%
• 5 years: -98.66%
• 10 years: -99.40%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Employees: 19

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

354% more call options, than puts

Call options by funds: $109K | Put options by funds: $24K

135% more capital invested

Capital invested by funds: $4.73M [Q2] → $11.1M (+$6.37M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

0.33% less ownership

Funds ownership: 20.87% [Q2] → 20.54% (-0.33%) [Q3]

3% less funds holding

Funds holding: 39 [Q2] → 38 (-1) [Q3]

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

56% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 9